mHealth Medication Safety Intervention
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/11/2018 |
| Start Date: | October 11, 2017 |
| End Date: | April 30, 2020 |
| Contact: | David Taber, PharmD,MS |
| Email: | taberd@musc.edu |
| Phone: | 843-792-2724 |
Improving Transplant Medication Safety Through A Pharmacist-Empowered, Patient-Centered, Mhealth-Based Intervention (TRANSAFE Rx Study)
TRANSAFE Rx is a 12-month, parallel two-arm, 1:1 randomized controlled clinical trial,
involving 136 participants (68 in each arm) measuring the clinical and economic effectiveness
of a pharmacist-led intervention, which utilizes an innovative mHealth application to improve
medication safety and health outcomes, as compared to usual post-transplant care. The primary
goal of the TRANSAFE Rx study is to demonstrate significant reductions in med safety issues
leading to reduced healthcare resource utilization in kidney transplantation through a
pharmacist-led, mHealth-enabled, intervention. This study will provide detailed and novel
information on the incidence, etiologies and outcomes of med errors and adverse drug events
in this high-risk population; while also demonstrating the effectiveness of this intervention
on reducing the incidence and impact of med safety issues in kidney transplantation.
involving 136 participants (68 in each arm) measuring the clinical and economic effectiveness
of a pharmacist-led intervention, which utilizes an innovative mHealth application to improve
medication safety and health outcomes, as compared to usual post-transplant care. The primary
goal of the TRANSAFE Rx study is to demonstrate significant reductions in med safety issues
leading to reduced healthcare resource utilization in kidney transplantation through a
pharmacist-led, mHealth-enabled, intervention. This study will provide detailed and novel
information on the incidence, etiologies and outcomes of med errors and adverse drug events
in this high-risk population; while also demonstrating the effectiveness of this intervention
on reducing the incidence and impact of med safety issues in kidney transplantation.
Inclusion Criteria:
- Kidney transplant recipient between 6 and 36 months post-transplant
- At least 18 years of age
- Transplant MD agrees that patient is eligible to participate
Exclusion Criteria:
- Multi-organ recipient
- Patient is incapable of:
- Measuring their own blood pressure and glucose (if applicable)
- Self-administering medications
- Speaking, hearing and reading English
- Utilizing the mHealth application, after training
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: David Taber, PharmD, MS
Phone: 843-792-7558
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
